Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 NEWTON, MA and GENEVA, SWITZERLAND – October 7, 2021 – Acer …
News
Rapid Micro Biosystems Announces Pricing of Initial Public Offering
Source: Rapid Micro Biosystems, Inc.July 14, 2021 21:30 ETLOWELL, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“RapidMicro”), an innovative life sciences …
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021
Following Pre-NDA Meeting with FDA
NEWTON, MA and GENEVA, SWITZERLAND – May 25, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies …
COVID Innovations March 25th, 2021
Author: Dr. Linda Morrow – March 25th, 2021 Imagine a pandemic without having to shut down our lives. Imagine governments and industry working cooperatively to develop diagnostic and vaccine …
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021 GENEVA, SWITZERLAND and …
Access Vascular, Inc. Secures $20 Million in Series B Financing
Bedford, MA – 03 March, 2021- Access Vascular, Inc., a company addressing the most common and costly venous access complications, today announced it has closed on a Series B round of financing. …